Posastiuc Florin Petrișor, Constantin Nicolae Tiberiu, Domain Guillaume, Soom Ann Van, Diaconescu Alexandru Ilie, Codreanu Mario Darius
Department of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium.
Department of Clinical Sciences II, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine of Bucharest, 050097 Bucharest, Romania.
Vet Sci. 2025 Jan 19;12(1):70. doi: 10.3390/vetsci12010070.
Benign prostatic hyperplasia (BPH) is a common condition in intact male dogs and a leading cause of subfertility. While surgical and chemical castration are effective treatments for BPH, managing this condition in breeding dogs is challenging due to the desire to preserve reproductive function. This study systematically reviews medical treatments for BPH that maintain breeding potential. Thus, a comprehensive literature search was conducted across four databases (CAB Direct, Scopus, PubMed, and Web of Science) to identify peer-reviewed studies published between 2000 and 2024, following PRISMA guidelines. Specific inclusion and exclusion criteria were applied, and a risk of bias assessment was performed using a modified Cochrane tool. A total of 35 studies were included, evaluating therapies such as finasteride, osaterone acetate, tamoxifen, and others, with outcomes including prostate size, sperm quality, hormonal levels, and tissue morphology. Evidence suggests that osaterone acetate and finasteride are acceptable treatments for BPH in breeding dogs, in spite of a still debatable effect on some sperm characteristics. Therapies like tamoxifen and acyline should be excluded due to their detrimental effects on reproductive function. Further research is required for apparently promising approaches concerning tadalafil, anastrazole, mepartricin, and .
良性前列腺增生（BPH）是未绝育雄性犬类的常见病症，也是导致生育力低下的主要原因。虽然手术去势和化学去势是治疗BPH的有效方法，但由于希望保留繁殖功能，因此在种犬中管理这种病症具有挑战性。本研究系统地综述了维持繁殖潜力的BPH药物治疗方法。因此，按照PRISMA指南，在四个数据库（CAB Direct、Scopus、PubMed和Web of Science）中进行了全面的文献检索，以确定2000年至2024年期间发表的同行评审研究。应用了特定的纳入和排除标准，并使用改良的Cochrane工具进行了偏倚风险评估。总共纳入了35项研究，评估了非那雄胺、醋酸奥沙睾酮、他莫昔芬等疗法，结果包括前列腺大小、精子质量、激素水平和组织形态。有证据表明，尽管醋酸奥沙睾酮和非那雄胺对某些精子特征的影响仍有争议，但它们是种犬BPH的可接受治疗方法。像他莫昔芬和阿西利内这样的疗法因其对生殖功能的有害影响而应被排除。对于西地那非、阿那曲唑、麦地霉素等明显有前景的方法，还需要进一步研究。
